{"entity":{"id":"jan-vermorken","kind":"person","name":"Jan B. Vermorken","aka":[],"tldr":"Led EXTREME and TAX 323, which defined the chemotherapy standards for head and neck cancer for a decade.","summary":"Jan Vermorken (Antwerp University Hospital) was principal investigator of EXTREME, which showed adding cetuximab to platinum-fluorouracil improves survival in recurrent or metastatic head and neck cancer and became the comparator arm for KEYNOTE-048, and of TAX 323, which established docetaxel-based induction chemotherapy. He also led early cisplatin-based trials in cervical cancer and has chaired EORTC head and neck research.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermorken%20JB%5BAuthor%5D%20head%20neck%20cetuximab"}],"tags":["head-and-neck","chemotherapy","eortc"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":["monoclonal-antibody","platinum"],"targets":["egfr"],"drugs":[],"companies":[],"institutions":["antwerp-university-hospital"],"pathways":[],"terms":[],"trials":["extreme"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Emeritus Professor of Oncology, Antwerp University Hospital","institutionId":"antwerp-university-hospital","specialisms":["Head and neck cancer","Chemotherapy","Anti-EGFR therapy","Cervical cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vermorken%20JB%5BAuthor%5D%20head%20neck%20cetuximab"}],"papers":[{"title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer (EXTREME)","journal":"NEJM","year":2008,"doi":"10.1056/NEJMoa0802656"},{"title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323)","journal":"NEJM","year":2007,"doi":"10.1056/NEJMoa071028"}],"orcid":"0000-0001-8515-7848"},"route":"/people/jan-vermorken/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"institution":[{"id":"antwerp-university-hospital","kind":"institution","name":"Antwerp University Hospital (UZA)","route":"/institutions/antwerp-university-hospital/"}],"trial":[{"id":"extreme","kind":"trial","name":"EXTREME","route":"/trials/extreme/"}]}}